DOP20070101A - Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida. - Google Patents

Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.

Info

Publication number
DOP20070101A
DOP20070101A DO2007P000101A DOP20070101A DOP20070101A DO P20070101 A DOP20070101 A DO P20070101A DO 2007P000101 A DO2007P000101 A DO 2007P000101A DO P20070101 A DOP20070101 A DO P20070101A DO P20070101 A DOP20070101 A DO P20070101A
Authority
DO
Dominican Republic
Prior art keywords
humanized
human
function
integrin
reduced immunogenicity
Prior art date
Application number
DO2007P000101A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopf
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Petit-Frere
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP20070101A publication Critical patent/DOP20070101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

POLIPEPTIDOS RECOMBINANTES HUMANOS O HUMANIZADOS QUE SE UNEN A LA INTEGRINA ?5?1 CON GRAN AFINIDAD Y BLOQUEAN SU FUNCION. ADEMAS, SE DESCRIBEN APLICACIONES DE DIAGNOSTICO Y FARMACEUTICO DE LOS POLIPEPTIDOS.
DO2007P000101A 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida. DOP20070101A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
DOP20070101A true DOP20070101A (es) 2007-12-30

Family

ID=38659612

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2007000101A DOP2007000101A (es) 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la función de la integrina a5b1 humanos y humanizados de gran afinidad con inmunogenicidad reducida
DO2007P000101A DOP20070101A (es) 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2007000101A DOP2007000101A (es) 2006-05-24 2007-05-22 Anticuerpos bloqueantes de la función de la integrina a5b1 humanos y humanizados de gran afinidad con inmunogenicidad reducida

Country Status (23)

Country Link
US (1) US20090081207A1 (es)
EP (1) EP2032605A2 (es)
JP (1) JP2009537158A (es)
KR (1) KR20090027218A (es)
CN (1) CN101495515A (es)
AR (1) AR061107A1 (es)
AU (1) AU2007253586A1 (es)
BR (1) BRPI0711796A2 (es)
CA (1) CA2652886A1 (es)
CL (1) CL2007001488A1 (es)
CR (1) CR10456A (es)
DO (2) DOP2007000101A (es)
EA (1) EA200802348A1 (es)
EC (1) ECSP088909A (es)
MA (1) MA30425B1 (es)
MX (1) MX2008014910A (es)
NO (1) NO20085362L (es)
PE (1) PE20080100A1 (es)
TN (1) TNSN08469A1 (es)
TW (1) TW200817433A (es)
UY (1) UY30362A1 (es)
WO (1) WO2007134876A2 (es)
ZA (1) ZA200810850B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AR060040A1 (es) 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
WO2009100110A1 (en) * 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
CN103755808B (zh) * 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
BR112013000452A2 (pt) * 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
NZ627963A (en) 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
RU2681994C2 (ru) * 2012-12-26 2019-03-14 Онкосинерджи, Инк. КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
MX382540B (es) * 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis
WO2021015336A1 (ko) * 2019-07-24 2021-01-28 가톨릭대학교 산학협력단 αVβ3 인테그린 표적 단일 도메인 항체
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
MXPA05005558A (es) * 2002-11-26 2005-07-26 Protein Design Labs Inc Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis.
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
ATE531388T1 (de) * 2004-03-24 2011-11-15 Abbott Biotherapeutics Corp Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
AR060040A1 (es) * 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1

Also Published As

Publication number Publication date
AU2007253586A1 (en) 2007-11-29
CN101495515A (zh) 2009-07-29
TW200817433A (en) 2008-04-16
CR10456A (es) 2009-02-26
AR061107A1 (es) 2008-08-06
ZA200810850B (en) 2010-05-26
US20090081207A1 (en) 2009-03-26
JP2009537158A (ja) 2009-10-29
MA30425B1 (fr) 2009-05-04
EP2032605A2 (en) 2009-03-11
EA200802348A1 (ru) 2009-08-28
WO2007134876A2 (en) 2007-11-29
WO2007134876A3 (en) 2008-03-27
NO20085362L (no) 2009-02-23
MX2008014910A (es) 2009-01-23
KR20090027218A (ko) 2009-03-16
ECSP088909A (es) 2008-12-30
TNSN08469A1 (en) 2010-04-14
DOP2007000101A (es) 2007-12-31
WO2007134876A8 (en) 2009-07-02
CA2652886A1 (en) 2007-11-29
BRPI0711796A2 (pt) 2011-12-06
CL2007001488A1 (es) 2008-01-04
PE20080100A1 (es) 2008-04-18
UY30362A1 (es) 2008-01-02

Similar Documents

Publication Publication Date Title
CR10456A (es) ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5B1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
EP4271413A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
CR20140398A (es) Anticuerpos e inmunoconjugados anti-cd22
MX386879B (es) Sistemas de fluidos de punto de cuidado y usos de los mismos.
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
HUE044756T2 (hu) HER-3 elleni antitestek és alkalmazásuk
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
DE60202841D1 (de) Anzeigegerät mit Drahtgitter-Strahlteiler und Kompensator
BRPI0717367A2 (pt) Di-hidropirazolonas substituídas e sua aplicação.
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
HN2006015949A (es) Anticuerpos de p-caderina
BRPI0715298A2 (pt) Compostos substuídos de tetrahidropirrolipiperazina tendo afinidade com o canal kcnq2/3 k+ e sua aplicação em medicamentos.
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
ES2448492T8 (es) Procedimientos para la envoltura conjunta de bolsas con su contenido, y máquina de aplicación
EP4380631A4 (en) Cd3 targeting antibodies and uses thereof
BR0207616B1 (pt) material composto de policarbonato em camadas e seu uso.